Conference Day Two | Thursday, June 5

7:30 am Check-In & Coffee

8:20 am Chair’s Opening Remarks

8:30 am Envisioning the Future Evolution of In Vivo Hematopoietic Stem Cell Engineering & Gene Editing Treatments

Synopsis

  • Establishing in vivo HSC engineering approaches by leveraging validated biology from ex vivo therapeutics to eliminate patient and manufacturing burdens and expand treatable patient populations
  • Combining large gene insertions and lineage-specific control in vivo to enable multicellular interventions to diversify treatment opportunities
  • Evaluating in vivo HSC engineering opportunities in gene editing methods, including Cas9, base editing, prime editing, and targeted insertions, alone and in combination with insertions

9:00 am Roundtable Discussion: Harnessing Investor & Pharma Insights to Facilitate Successful, Lasting, Progressive Collaborations & Investments

Synopsis

  • Revealing the considerations pharma companies face when deciding to enter the market
  • Delving into the investors’ mindset to understand what drives their expectations, concerns and evaluation of biotech investments
  • Discussing the factors that determine the commercial viability of treatmentsΒ 

9:45 am Morning Break & Networking

10:15 am Unlocking Novel Strategies & Technologies to Produce, Targeted, Stable Vehicle Delivery Options & Stimulate Clinical Progression

Synopsis

  • Navigating complex design processes to produce delivery vehicles that protect the therapeutic payload, enhance stability and facilitate targeted delivery
  • Spotlighting novel technologies to transform vehicle delivery manufacturing and produce safe, stable delivery vehicles

10:45 am Leveraging Delivery Model Insights to Engineer Enhanced Delivery Vehicles to Refine Target Specificity & Reduce Immunogenicity

Synopsis

  • Identifying and discussing strategies for vehicle optimization to ensure efficient treatment delivery for a variety of payloads
  • Exploring the mechanisms that drive immunogenicity and how we can overcome them
  • Utilizing enhanced delivery vehicles to effectively balance treatment potency and toxicity prevention

11:15 am Roundtable Discussion: The Transgene Insertion or Transient Expression Debate: Exploring the Superior Method for Payload Delivery

  • Adrian Bot Founding Chief Scientific Officer & Executive Vice President - Research & Development, Capstan Therapeutics

Synopsis

  • Exploring which process is best utilized for curative or symptom regulation improvements in oncology and autoimmune-based diseases
  • Discussing the efficacy and safety impacts of each payload delivery method to identify the premier delivery method
  • Evaluating preclinical data highlighting the persistence and treatment response outcomes to provide insight into possible clinical outcomesΒ 

12:00 pm Lunch Break & Networking

1:00 pm Reimagining CAR & Protein Manufacturing Processes to Revolutionize Treatment Payload Manufacturing

Synopsis

  • Modifying the CAR manufacturing process to overcome manufacturing challenges caused by the hydrophobic domain of CARs
  • Understanding the complexities of protein multidomain to enhance and simplify the protein purification process during manufacturing
  • Exploring cargo expression suppression in lentiviral manufacturing to maximize efficient production and prevent interference in particle productionΒ 

1:30 pm Navigating Protein Delivery Mechanisms to Overcome Tolerance & Immunogenicity

Synopsis

  • Navigating protein delivery mechanisms of action in the muscle or brain to explore delivery beyond the liver
  • Highlighting factors that mediate tolerance to foreign viral capsids produced by AAV delivery
  • Understanding the extent to which protein-induced immunogenicity impacts therapy delivery, potency and efficiency to improve treatment efficacy

2:00 pm Panel Discussion: β€˜Evaluating LVV & LNP Delivery Method Clinical Potential in In Vivo Cell & Gene Therapies

Synopsis

  • Discussing the long-term efficacy and durability of LVV and LNP-based therapies to understand the impact of delivery on disease regression and treatment
  • Exploring how LVV, LNP and RNP technologies can evolve to produce enhanced therapeutic outcomes
  • Evaluating the potential of the delivery vehicles to deliver complex payloads

2:45 pm Afternoon Break & Networking

3:15 pm Exploring the Possibilities of In Vivo Gene Editing to Diversify Treatment Opportunities

Synopsis

  • Exploring how in vivo genetic editing could unlock treatments for previously untreatable genetic disorders and complex diseases
  • Understanding how advances in genetic editing will enable more tailored, patient-specific therapies for improved outcomes
  • Discuss the hurdles of ensuring sustained effects and safety of in vivo genetic editing therapies over time

3:45 pm Shaping the Next Generation of In Vivo Gene Editing

  • Eric Kmiec Founder, Chief Executive & Scientific Officer, CorriXR Therapeutics

Synopsis

  • Explore cutting-edge technologies improving the accuracy and efficiency of in vivo genetic editing techniques, such as CRISPR and base editing
  • Address the evolving methods to enhance delivery systems, ensuring targeted and efficient gene editing in diverse tissues and organs
  • Delving into metabolism changes as a result of in vivo gene editing
  • Sharing preclinical successes

4:15 pm Reimagining Gene Editing Capabilities: Exploring In Situ Gene Editing of the Microbiome to Expand Addressable Targets

Synopsis

  • Exploring bacterial expression from the core microbiome treat immune and chronic diseases
  • Highlighting bacterial viral vectors as effective delivery vehicles for gene editing payloads

4:45 pm Chair’s Closing Remarks

5:00 pm End of Conference Day Two